The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...

Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...

The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema ...

CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such ...

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, issues at a Novo plant are ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

Early packaging decisions can make or break your drug's market launch. Choose the best packaging and secure the future.